Quarterly ResultApr 29, 2026, 07:07 AM
IEX Q1 Sales $887M (+9%); Adj. EPS $2.00 (+14%); Raises FY26 Guidance
AI Summary
IDEX Corporation reported strong first-quarter 2026 financial results, with sales increasing 9% to $887 million and adjusted diluted EPS rising 14% to $2.00. The company achieved record orders of $988 million, up 13% reported and 10% organically, driven by momentum in its Health & Science Technologies segment. Based on this performance, IDEX is raising its full-year 2026 organic sales growth and adjusted EPS guidance ranges. The company also returned $76 million to shareholders via share repurchases and $53 million via dividends.
Key Highlights
- Sales of $887 million increased 9% reported and 5% organically year-over-year.
- Adjusted diluted EPS was $2.00, a 14% increase compared to the prior year period.
- Record orders reached $988 million, up 13% reported and 10% organically.
- Returned $76 million to shareholders via share repurchases and $53 million via dividends.
- Full-year 2026 organic sales guidance raised to 3-4% from previous 1-2%.
- Full-year 2026 adjusted diluted EPS guidance raised to $8.35-$8.55 from $8.15-$8.35.
- Health & Science Technologies segment sales grew 17% reported and 11% organically to $398.4 million.
- Fluid & Metering Technologies segment sales increased 4% reported and 2% organically to $301.5 million.